Sens. Dianne Feinstein, D-Calif., Jeff Merkley, D-Ore., and Alex Padilla, D-Calif., asked the commerce secretary and U.S. trade representative to work to convince China and the European Union to lift their retaliatory tariffs on American wine. In both cases, the tariffs were imposed in response to U.S. tariffs on those countries' exports. The three said in the May 11 letter: "Wineries in our states are already under siege by the pandemic, wildfires, and now drought. Many will not survive if they are also asked to indefinitely sustain a damaging trade war."
U.S. Trade Representative Katherine Tai, in her second day of testimony on Capitol Hill, heard again and again from members of Congress who are hearing from companies in their districts that they want Section 301 tariff exclusions back. She heard repeatedly that the 9% countervailing duties on Canadian lumber are making a bad situation worse. And she heard that the Miscellaneous Tariff Bill and Generalized System of Preferences benefits program should be renewed. On each topic, both Democrats and Republicans shared concerns, though on GSP, Republicans only spoke of the cost to importers, while Democrats worried about the effects of GSP on the eligible countries. Tai testified for more than four hours in front of the House Ways and Means Committee on May 13.
U.S. Trade Representative Katherine Tai generally avoided being pinned down on timing as she was asked about rekindling trade negotiations with the United Kingdom and Kenya, the pause on tariffs on European imports, and a solution for steel overcapacity that could make way for the lifting of Section 232 tariffs.
One Democrat and one Republican from each chamber sent a letter to U.S. Trade Representative Katherine Tai, asking the administration to reexamine the decision to withdraw from the Trans-Pacific Partnership in 2017, a decision they called “misguided and short-sighted.” The May 5 letter, led by Sen. Tom Carper of Delaware, a close ally to President Joe Biden, also acknowledged that “there are significant political obstacles to negotiating an agreement to rejoin the TPP in its current form.” But Carper, Sen. John Cornyn, R-Texas, Rep. Stephanie Murphy, D-Fla., and Rep. Adam Kinzinger, R-Ill., said there should be an effort to determine the best course for engagement with the countries that continued on without the U.S. to see how they could build on recent trade agreements.
U.S. Trade Representative Katherine Tai announced May 5 that the U.S. will support an intellectual property waiver for COVID-19 vaccines, but she cautioned that negotiating the language in Geneva will take time, because of both the need for consensus at the World Trade Organization and the “complexity of the issues.” Top Democrats in Congress welcomed the announcement. Tai also said the administration will work to increase production of raw materials for vaccines.
U.S. Trade Representative Katherine Tai will testify on the administration's trade policy agenda next week, appearing May 12 at 9:30 a.m. before the Senate Finance Committee and May 13 at 10 a.m. before the House Ways and Means Committee.
Export Compliance Daily is providing readers with the top stories for April 26-30 in case you missed them. You can find any article by searching on the title or by clicking on the hyperlinked reference number.
U.S. Trade Representative Katherine Tai announced May 5 that the U.S. will support an intellectual property waiver for COVID-19 vaccines, but cautioned that negotiating the language in Geneva will take time, because of the need for consensus at the World Trade Organization, and because of the “complexity of the issues.” Top Democrats in Congress welcomed the announcement. Tai also said the administration will work to increase production of raw materials for vaccines, which has been the constraint so far for Indian vaccine manufacturers. Pfizer has expressed interest in manufacturing in India if it would speed approval of its vaccine; India currently does not allow imports of Johnson & Johnson, Pfizer or Moderna vaccines.
Member nations of the World Trade Organization agreed to continue consideration of the temporary waiver on certain intellectual property requirements for COVID-19 vaccine production, at an April 30 meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), the WTO announced in a press release. The waiver proposal was submitted by South Africa and India but faces opposition from some of the globe's wealthiest countries, such as the U.S., the United Kingdom and countries in the European Union, that have blocked the plan. The chair of the council is tasked with reporting to the General Council on the group's decision regarding the IP waiver at the next meeting on May 5-6.
With the administration's desire to address root causes for migration from Central American countries, U.S. Trade Representative Katherine Tai said the free trade agreement that covers that region, and the Dominican Republic, has been “very much on my mind recently.”